Sign inJoin waitlistJoin the waitlist

MacRae Linton

Director, Vanderbilt Lipid Clinic · Vanderbilt University Medical Center

Credentials: · · ·

History

Atherosclerosis Research · Vanderbilt University Medical Center
Present
Vanderbilt Univ Sch of Med · Vanderbilt University Medical Center
Present
Vanderbilt Univ Sch of Med
Present

Endocrinology, Diabetes, and Metabolism
University of California-San Francisco
1989–1991
Cardiovascular Disease
UCSF Medical Center
1988–1991
Internal Medicine
Vanderbilt University Medical Center
1985–1988
Univ of Tennessee Coll of Med
1981–1985

Research

Current perspectives on statins
Review · Circulation · 2000 · Last of 3 authors · 978 citations
Premature coronary-artery atherosclerosis in systemic lupus erythematosus
New England Journal of Medicine · 2003 · 675 citations
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
Nature · 2007 · 606 citations

SF
Sergio Fazio
173 papers
Valentina Kon
29 papers
Stephen Young
18 papers
Agnes Fogo
15 papers
CS
Charles Stein
10 papers
RF
Robert Farese
9 papers
Amanda Doran
8 papers
Cecilia Chung-Nakandakari
8 papers
DD
Dwayne Dove
8 papers · 1 as a resident
Daniel Rader
7 papers
James May
7 papers
Joshua Knowles
7 papers

Grants

HDL Function in Human Disease
National Heart, Lung, and Blood Institute · P01
Contact PI · $24.7M · Vanderbilt University Medical Center
2014–2025
Vanderbilt Mouse Metabolic Phenotyping Center
National Institute of Diabetes and Digestive and Kidney Diseases · U2C
Project lead · $1.4M · Vanderbilt University
2022
Macrophage SR-BI Regulates Autophagy, Angiogenin and tRNA-Derived Small RNAs
National Heart, Lung, and Blood Institute · R01
Contact PI · $2.1M · Vanderbilt University Medical Center
2016–2020
Mechanisms for Dysfunctional HDL Formation in Familial Hypercholesterolemia
National Heart, Lung, and Blood Institute · R01
Contact PI · $919.7K · Vanderbilt University
2012–2016

Clinical trials

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Principal investigator · Recruiting · Phase 2
Vanderbilt University Medical Center
2024–2027
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030